Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Nov 01, 2022 11:56am
158 Views
Post# 35063331

RE:RE:RE:RE:RE:Official termination of distribution rights in Europe

RE:RE:RE:RE:RE:Official termination of distribution rights in Europe

It's crazy. If they make a positive forward looking statements and it doesn't pan out they get kicked (NASH). 

If they say nothing, wait for the picture to become clearer before saying something they get kicked (cancer).

They (and us) are trying to deal with the uncertainty of biotech (it's a big part of the story). I don't know either are doing a good job of it. Ultimately success is the only real answer, that's eluded them in their last two projects (Trogarzo and NASH). It's coming slow (if at all) in cancer, that might change rapidly for the better or worse or it might not. I'm still hopeful.


Biobob wrote: That and the STRONG negociation position in P3 NASH/Partner.. we now are loonking at P2/3 and no partner like a year later.  No wonder they don't tell us anything about the cancer trial, maybe they learned it's better this way since they never make the deadline. As long as they succeed in the end.  At that point averything that was said on this board will vanish in oblivion and a new era will begin... amen.

 

<< Previous
Bullboard Posts
Next >>